Keyword Connections

kinase inhibitors

Journals

1

1 bioorganic & medicinal chemistry

Research Groups

0

No Research Group Connected

Bibliographies

47

1 Pyrazolopyrimide library screening in glioma cells discovers highly potent antiproliferative leads that target the PI3K/mTOR pathway.

2 a cell biologist’s field guide to aurora kinase inhibitors

3 PIM kinase inhibitors: Structural and pharmacological perspectives.

4 Discovery and biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors

5 Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595.

6 Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis.

7 Machine Learning Models for Accurate Prediction of Kinase Inhibitors with Different Binding Modes.

8 ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.

9 Synthesis and anticancer activity of some pyrido[2,3-]pyrimidine derivatives as apoptosis inducers and cyclin-dependent kinase inhibitors.

10 Janus kinase inhibitors: jackpot or potluck?

11 Pharmacokinetics and in Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis

12 Structural basis of pyrazolopyrimidine derivatives as CAMKIIδ kinase inhibitors: insights from 3D QSAR, docking studies and in silico ADMET evaluation

13 Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors

14 Thiazolidine-2,4-dione-based irreversible allosteric IKK-β kinase inhibitors: Optimization into in vivo active anti-inflammatory agents.

15 Thiazolidine-2,4-dione-based irreversible allosteric IKK-β kinase inhibitors: Optimization into in vivo active anti-inflammatory agents

16 Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis.

17 The prognostic role of BRAF and WNT pathways activation in kinase inhibitors-naïve clinical stage III cutaneous melanoma.

18 Synthesis, and anti-proliferative, Pim-1 kinase inhibitors and molecular docking of thiophenes derived from estrone.

19 RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice

20 structure-based discovery of a series of 5h-pyrrolo[2,3-b]pyrazine fgfr kinase inhibitors

21 checkpoint molecule pd-1-assisted cd8+ t lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors

22 rho kinase inhibitors for glaucoma treatment - review

23 can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?

24 tyrosine kinase inhibitors in egfr-mutated large-cell neuroendocrine carcinoma of the lung a case report

25 identification of two kinase inhibitors with synergistic toxicity with low-dose hydrogen peroxide in colorectal cancer cells in vitro

26 chemotherapy and egfr tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients

27 importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance

28 phosphatidyl-inositol-3 kinase inhibitors regulate peptidoglycan-induced myeloid leukocyte recruitment, inflammation, and neurotoxicity in mouse brain

29 Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2

30 severe adverse effects associated with tyrosine kinase inhibitors therapy in chronic myeloid leukaemia – case reports and literature review

31 crosstalk between substrates and rho-associated kinase inhibitors in cryopreservation of tissue-engineered constructs

32 Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study.

33 investigations on binding pattern of kinase inhibitors with pparγ: molecular docking, molecular dynamic simulations, and free energy calculation studies

34 increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis

35 alignment independent 3d-qsar, quantum calculations and molecular docking of mer specific tyrosine kinase inhibitors as anticancer drugs

36 tyrosine kinase inhibitors and pregnancy

37 template-based de novo design for type ii kinase inhibitors and its extented application to acetylcholinesterase inhibitors

38 outcomes of research biopsies in clinical trials of egfr mutation-positive non-small cell lung cancer patients pretreated with egfr-tyrosine kinase inhibitors

39 tyrosine kinase inhibitors therapy related neutropenia and thrombocythopenia correction in cml patients

40 several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, as new anti-malarial agents

41 docking and 3d qsar studies on p38α map kinase inhibitors

42 Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the Gene Have Durable Responses to ALK Kinase Inhibitors.

43 The selectivity of protein kinase inhibitors: a further update

44 The selectivity of protein kinase inhibitors: a further update

45 Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors.

46 Design, synthesis, and bioactivity evaluation of macrocyclic benzo[b]pyrido[4,3-e][1,4]oxazine derivatives as novel Pim-1 kinase inhibitors

47 EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.